Intellia Therapeutics Inc
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$79.00 | Qfx | Dqmyfmkyc |
Intellia Reports Solid Q2 Results In Line With Expectations, Maintaining $85 FVE, Shares Undervalued
Intellia Therapeutics reported solid second-quarter results in line with our expectations, and the company is continuing to make progress bringing its gene-editing medicines to market. We maintain our fair value estimate of $85 per share and view the stock as undervalued, currently trading in 4-star territory. Our no-moat rating and positive moat trend remain unchanged. Collaboration revenue totaled $14 million for the quarter, which represents 25% growth from the first quarter. The increase was primarily driven by Intellia’s collaborations with AvenCell and Kyverna.